Health · Pharma & Biotech · 7 hrs ago

Expert warns of future fight over access to newer obesity drugs

Expert warns of future fight over access to newer obesity drugs

Ken Shadlen warns that access to obesity medicines could become a global battleground.

Shadlen is a London School of Economics professor who studies pharmaceutical and health regulation.

Lower-cost generic versions of semaglutide are now available in some countries and are expected to reach others soon.

Semaglutide is sold by Novo Nordisk as Wegovy to help treat obesity.

Drugmakers are developing newer GLP-1 medicines that are forecast to work better, cause fewer side effects or be easier to use.

These changes could help more people get support for losing weight, but access may be especially contested in lower-income countries.

Drugmakers, governments and patients may soon face challenges over who can get these medicines.

1 source

Related